Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations
- PMID: 22014044
- DOI: 10.1111/j.1365-2559.2011.03941.x
Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations
Abstract
Aims: NIMA-related kinase 2 (Nek2) and β-catenin are important centrosome regulatory factors. The aim of this study was to detect the possible disparity in their expression among normal breast tissue, invasive ductal carcinoma (IDC), concomitant ductal carcinoma in situ (DCIS), and pure DCIS, and to explore its correlation with clinicopathological factors.
Methods and results: We used immunohistochemistry to detect protein expression of Nek2 and β-catenin in breast cancer tissues from 60 cases of pure DCIS, 348 cases of IDC and 137 cases of concomitant DCIS with that in normal breast tissues from the same 137 concomitant DCIS patients as controls. As compared with normal tissue, expression of Nek2 and β-catenin in the cytoplasm was significantly increased in IDC and DCIS (P < 0.05), and variation in expression was also observed in different grades of IDC (P < 0.01). Also, cytoplasmic expression of Nek2 and and of β-catenin were correlated with each other in IDC and DCIS (P < 0.01). In addition, they were both related to Ki67 immunoreactivity (P < 0.05). Furthermore, our study also revealed a correlation between their expression and some clinicopathological factors. We found that Nek2 cytoplasmic expression was associated with grade and tumour size (P < 0.01) in IDC, whereas β-catenin cytomembrane expression showed significant variation with grades, TNM stages, lymphoid node status, oestrogen receptor status, and molecular subtype (P < 0.05); a difference in expression was also observed between IDC and DCIS (P < 0.05). Also, β-catenin cytoplasmic expression was associated with TNM stage (P < 0.05). Expression of Nek2 at the mRNA level was detected in 50 pairs of breast cancer specimens and matched normal tissues by reverse transcriptase polymerase chain reaction, and the result showed increased expression in IDC.
Conclusions: This study suggests that abnormal expression of Nek2 and β-catenin might be one of the mechanisms of tumorigenesis, especially of abnormal tumour proliferation. They may represent new potential targets for therapeutic intervention.
2011 Blackwell Publishing Limited.
Similar articles
-
Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer.Exp Mol Pathol. 2016 Feb;100(1):177-83. doi: 10.1016/j.yexmp.2015.12.012. Epub 2015 Dec 22. Exp Mol Pathol. 2016. PMID: 26721716
-
Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.Breast Cancer. 2011 Oct;18(4):286-91. doi: 10.1007/s12282-009-0192-y. Epub 2010 Feb 9. Breast Cancer. 2011. PMID: 20143189
-
[Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].Zhonghua Bing Li Xue Za Zhi. 2013 Apr;42(4):257-61. doi: 10.3760/cma.j.issn.0529-5807.2013.04.010. Zhonghua Bing Li Xue Za Zhi. 2013. PMID: 23928534 Chinese.
-
miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ.Am J Pathol. 2018 Mar;188(3):542-549. doi: 10.1016/j.ajpath.2017.11.003. Epub 2017 Dec 12. Am J Pathol. 2018. PMID: 29246496 Free PMC article. Review.
-
Identifying progression predictors of breast ductal carcinoma in situ.J Clin Pathol. 2017 Feb;70(2):102-108. doi: 10.1136/jclinpath-2016-204154. Epub 2016 Nov 18. J Clin Pathol. 2017. PMID: 27864452 Review.
Cited by
-
Molecular modeling and docking of small molecule inhibitors against NEK2.Bioinformation. 2016 Apr 10;12(2):62-68. doi: 10.6026/97320630012062. eCollection 2016. Bioinformation. 2016. PMID: 28104962 Free PMC article.
-
Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition.PLoS One. 2013 Oct 17;8(10):e77553. doi: 10.1371/journal.pone.0077553. eCollection 2013. PLoS One. 2013. PMID: 24147022 Free PMC article.
-
NEK2 serves as a prognostic biomarker for hepatocellular carcinoma.Int J Oncol. 2017 Feb;50(2):405-413. doi: 10.3892/ijo.2017.3837. Epub 2017 Jan 3. Int J Oncol. 2017. PMID: 28101574 Free PMC article.
-
Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 Jul 18;38(1):316. doi: 10.1186/s13046-019-1311-z. J Exp Clin Cancer Res. 2019. PMID: 31319849 Free PMC article.
-
Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development.Molecules. 2022 Jan 6;27(2):347. doi: 10.3390/molecules27020347. Molecules. 2022. PMID: 35056661 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous